Pt. Finger et al., PD-103 VERSUS I-125 FOR OPHTHALMIC PLAQUE RADIOTHERAPY, International journal of radiation oncology, biology, physics, 27(4), 1993, pp. 849-854
Citations number
36
Categorie Soggetti
Oncology,"Radiology,Nuclear Medicine & Medical Imaging
Purpose: A dosimetry study comparing the use of I-125 vs. Pd-103 radio
active seeds for ophthalmic plaque brachytherapy. Methods and Material
s: Palladium-103 (Pd-103) seeds in ophthalmic plaques were used to tre
at 15 patients with intraocular malignant melanoma. Computer-aided sim
ulations were performed to evaluate the intraocular dose distribution
of I-125 versus Pd-103 ophthalmic plaques (delivering equivalent apex
doses). Seven target points were selected. Starting at the outer scler
al surface, four were located along the central axis of the plaque: th
e 1 mm point (the inner sclera), the 6 mm point, the tumors apex, and
the opposite eye wall. We also evaluated the fovea, optic nerve, and t
he lens because they were considered to be critical structures. Result
s: These studies demonstrated that the lower energy photons generated
by Pd-103 seeds (average 21 KeV) in ophthalmic plaques were more rapid
ly absorbed in tissue than photons generated by I-125 (average 28 KeV)
. Therefore, during ophthalmic plaque radiotherapy, Pd-103 photons wer
e found to be more rapidly absorbed within the tumor and less likely t
o reach most normal ocular structures. On average, the use of Pd-103 d
ecreased the dose to the fovea by 5.7%, to the optic nerve by 8.4%, to
the lens by 26%, and to the opposite eye wall by 38.4%. Conclusion: P
alladium-103 ophthalmic plaque brachytherapy resulted in slightly more
irradiation of the tumor and less radiation to most normal ocular str
uctures.